Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Screening plasma HIV-1 RNA ≥1000 c/mL~* Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection)~* Ability to understand and sign a written informed consent form~* Willingness to use approved methods of contraception to avoid pregnancy (women of child bearing potential only)~* Age equal to or greater than 18 years~Exclusion Criteria:~* Women who are pregnant or breastfeeding;~* Active Center for Disease and Prevention Control (CDC) Category C disease~* Moderate to severe hepatic impairment~* Anticipated need for HCV therapy during the study~* Allergy or intolerance to the study drugs or their components or drugs of their class~* Malignancy within the past 5 years~* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening~* Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any immunomodulator within 28 days of Screening~* Exposure to an agent with documented activity against HIV-1 in vitro or an experimental vaccine or drug within 28 days of first dose of study medication~* Primary viral resistance in the Screening result~* Verified Grade 4 laboratory abnormality~* ALT \>5 xULN~* ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with \>35% direct bilirubin);~* Estimated creatinine clearance \<50 mL/min~* Recent history (≤3 months) of upper or lower gastrointestinal bleed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1349572 (N=~394) (Type: EXPERIMENTAL): GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
- raltegravir (N=~394) (Type: ACTIVE_COMPARATOR): raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).